TYRA BIOSCIENCES INC (TYRA) Stock Price, Forecast & Analysis
NASDAQ:TYRA • US90240B1061
TYRA Key Statistics, Chart & Performance
The current stock price of TYRA is 33.88 USD. In the past month the price increased by 12.3%. In the past year, price increased by 189.33%.
TYRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TYRA. When comparing the yearly performance of all stocks, TYRA is one of the better performing stocks in the market, outperforming 97.35% of all stocks.
TYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYRA. While TYRA has a great health rating, there are worries on its profitability.
TYRA Financial Highlights
Over the last trailing twelve months TYRA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS decreased by -16.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37% | ||
| ROE | -39.81% | ||
| Debt/Equity | 0 |
TYRA Forecast & Estimates
16 analysts have analysed TYRA and the average price target is 42.59 USD. This implies a price increase of 25.69% is expected in the next year compared to the current price of 33.88.
TYRA Ownership
TYRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TYRA
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 60 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Company Info
TYRA BIOSCIENCES INC
2656 State Street
Carlsbad CALIFORNIA US
CEO: Todd Harris
Employees: 60
Phone: 16197284760
TYRA BIOSCIENCES INC / TYRA FAQ
What does TYRA do?
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 60 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Can you provide the latest stock price for TYRA BIOSCIENCES INC?
The current stock price of TYRA is 33.88 USD. The price increased by 1.74% in the last trading session.
Does TYRA BIOSCIENCES INC pay dividends?
TYRA does not pay a dividend.
How is the ChartMill rating for TYRA BIOSCIENCES INC?
TYRA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TYRA stock listed?
TYRA stock is listed on the Nasdaq exchange.
Would investing in TYRA BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TYRA.